

WEL CCGs/Barts Health NHS Trust FREESTYLE LIBRE® (FSL) MONITORING 6-9 MONTH REVIEW FORM

This completed form should be sent to the GP (copy provided to the patient/carer) after the 6-9 month review

GP Details

Name

Tel

Address

Postcode						
NHS No	NHS.net email					
DOB						
SEX: Male / Fema	ale					
Specialist Clinic	Details					
Clinician Name	Dotano		Contact	tel. number		
Clinic Name/Respo	inic Name/Responsible Consultant Name Hospital Name					
NHS.net email						
Signature (can be t	typed if completing	g electronically)				
Next clinic appointment Date FSL initiated						
The above patient complete either B	ox A or Box B):					•
complete either Book A – Not met	NHS England c			top prescribing FSL tient will be followed up at	(√ oı	
complete either Bound BOX A - Not met sensors. Alternate their next routine	NHS England c tive monitoring l appointment	has been advised a	nd the pat	tient will be followed up at	(√ or	x)
BOX A - Not met sensors. Alternat their next routine	NHS England c tive monitoring l appointment	has been advised a	nd the pat			x)
BOX A - Not met sensors. Alternate their next routine BOX B - Met NHS sensors	NHS England c tive monitoring appointment S England conti	has been advised a	nd the pat	tient will be followed up at	(√ or	x)
BOX B - Met NHS sensors OUTCOMES - After	NHS England c tive monitoring appointment S England continuer 6-9 months o	has been advised a nuation criteria. Ple f use, one or more	nd the pat ase contin	tient will be followed up at		x)
BOX B - Met NHS sensors OUTCOMES - After	NHS England c tive monitoring appointment S England continuer 6-9 months o	has been advised a	nd the pat ase contin	tient will be followed up at	(√ or	x)
BOX B - Met NHS sensors OUTCOMES - After	NHS England c tive monitoring appointment S England continuer 6-9 months o	has been advised a nuation criteria. Ple f use, one or more	ase continuof the following range	tient will be followed up at	(√ or	x)
BOX A - Not met sensors. Alternat their next routine BOX B - Met NHS sensors OUTCOMES - Aft	NHS England c tive monitoring appointment S England continuer 6-9 months o	nuation criteria. Ple f use, one or more mmol/mol),or time in	ase continuof the following range	tient will be followed up at	(√ or	x)
BOX A - Not met sensors. Alternat their next routine BOX B - Met NH3 sensors OUTCOMES - Aft Improvement in H Baseline HbA1C Date	NHS England c tive monitoring appointment S England continuer 6-9 months of bA1c of ≥ 0.4% (4	nuation criteria. Ple of use, one or more mmol/mol),or time in	ase continuof the follorange h review	nue to prescribe FSL owing has been achieved:	(√ or	x)
BOX A - Not met sensors. Alternat their next routine BOX B - Met NHS sensors OUTCOMES - Aft Improvement in H Baseline HbA1C Date Any reduction in e	NHS England cotive monitoring appointment S England continuer 6-9 months of bA1c of ≥ 0.4% (4) pisodes of diabet sychosocial wellbe	nuation criteria. Ple f use, one or more mmol/mol),or time in HbA1C at 6 – 9 mont Date	ase continuof the follorange h review	nue to prescribe FSL owing has been achieved:	(√ or	x)

Version: 1.1

Date

Patient Details

Surname

Forename

Address

Approved By: Waltham Forest and East London Medicines Optimisation and Commissioning Committee (WELMOCC)

Date

Date approved: 27/01/2021

Review date: 01/2024 or sooner if evidence of practice

changes

Acknowledgements: Adapted with kind permission from the South East London Area Prescribing Committee (SEL APC) Guidance for Flash Glucose Monitoring



Significant reduction in test strip use: safe and appropriate reduction of 8/day for adults or 7/day for children		
Other outcomes as agreed by Type 1 Specialist Diabetes MDT at initiation (please specify):		
OTHER REQUIREMENTS:		
I confirm that the patient has:		
Completed FSL monitoring education (online or in person)		
2. Scanned glucose levels no less than 8 times per day and use the sensor >70% of the time		
3. Attended regular reviews with the local clinical team		
o. Attoriada regular reviewe with the local cililidar todin		

At all subsequent routine face-to-face appointments, we will review progress against the agreed starting criteria. The patient has been informed and has signed an agreement to say that they understand that should there be sustained improvement against the agreed criteria that ongoing FSL sensor prescriptions will be recommended.

Yours sincerely Diabetes Specialist Team,

(Name of organisation)

cc Patient

Version: 1.1

Approved By: Waltham Forest and East London Medicines Optimisation and Commissioning Committee (WELMOCC)

Date approved: 27/01/2021

Review date: 01/2024 or sooner if evidence of practice

changes

Acknowledgements: Adapted with kind permission from the South East London Area Prescribing Committee (SEL APC) Guidance for Flash Glucose Monitoring